Nurix’s Senior Scientist of Medicinal Chemistry, Tim Kane, will present a poster on Nurix’s approach to discovering IRAK4 targeted protein degraders at the American Chemical Society Fall meeting taking place August 18-22, 2024. Learn more about this year’s meeting here: https://bit.ly/4d8ew1I #ACSFall2024
Nurix Therapeutics
Biotechnology
San Francisco, CA 16,850 followers
Targeted protein degradation is only the beginning. Blazing a new path in medicine.
Über uns
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
- Website
-
http://www.nurixtx.com
External link for Nurix Therapeutics
- Industrie
- Biotechnology
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- San Francisco, CA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2012
- Spezialitäten
- research, life sciences, and biotechnology
Standorte
-
Primäre
1700 Owens Street, Suite 205
San Francisco, CA 94158, US
-
8800 Technology Forest Pl
Building 100, Suite 200
The Woodlands, Texas 77381, US
Employees at Nurix Therapeutics
Aktualisierungen
-
In the U.S., lung cancers account for 1 in 5 of all cancer deaths. At Nurix, we’re using our targeted protein modulation platform to potentially improve outcomes for those facing a diagnosis of cancer, including lung cancer. https://bit.ly/3L7kMKK #WorldLungCancerDay
-
-
Today, Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will discuss the latest company updates in a fireside chat at the UBS Virtual Targeted Protein Degradation Day at 2:30 p.m. ET. Listen to the live or archived discussion here: https://lnkd.in/eecFcZyK
-
-
We continued to make solid progress in the second quarter of 2024, including reporting new positive clinical data on NX-5948 at #EHA2024 and strengthening our balance sheet with a $188M public offering. Learn more about our progress and future plans here: https://lnkd.in/e4fmcsBR
-
-
At #EHA2024 we presented new clinical data from the Phase 1a/b trial of BTK degrader, NX-5948 in relapsed or refractory B-cell malignancies. Data presented demonstrated an ORR of 69.2% in a heavily pretreated patient population of CLL patients and clinical responses were rapid and deepening with longer time on treatment. Read more in the full press release here: https://bit.ly/3VIT6Cf
-
-
Nurix team members are enjoying attending the Biotechnology Innovation Organization Convention. It's always a great time connecting with industry leaders, exploring groundbreaking innovations, and forging new partnerships that will shape the future of biotechnology. #BIO2024
-
-
Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m. ET. Listen to the live or archived presentation here: https://bit.ly/3yRXPZi
-
-
National Cancer Survivors Day is an annual, worldwide celebration to recognize cancer survivors, bring awareness to the ongoing challenges survivors face, and most importantly, celebrate life. At Nurix, we are developing novel therapies to potentially change the treatment landscape and increase the number of survivors of cancer. #NCSD #CancerSurvivorsDay
-
-
Nurix’s Research Associate of Analytical Chemistry, Shalya Masters, will present a poster presentation at the 36th International Symposium on Preparative and Process Chromatography taking place May 28-31, 2024. Learn more about the symposium here: https://www.prep2024.org/ #PREP2024
-
Nurix’s Senior Scientist of Analytical Chemistry, Amber Guillen, will present at the 36th International Symposium on Preparative and Process Chromatography on Thursday, May 30th at 3:00 p.m. ET. Learn more about the symposium here: https://www.prep2024.org/ #PREP2024
PREP 2024 / Philadelphia, PA, United States - May 28-31, 2024
prep2024.org
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 175.0M